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Cocrystals of Spironolactone and Griseofulvin Based on an in Silico 
Screening Method 
 
Tudor Grecu,a Rafel Prohens,b c James F. McCabe,a Elliot J. Carrington,d James S. Wright, d Lee 
Brammer,d and Christopher A. Hunter*e 
Cocrystal formation is considered as one of the most effective solid-state methods to alter the physicochemical properties 
of active pharmaceutical ingredients (APIs). In silico methods for cocrystal prediction are mostly based on structural and 
energetic considerations. We have developed a computational method that ranks the probability of cocrystal formation of 
APIs with large databases of crystal coformers (CCFs). This approach is based on using molecular electrostatic potential 
surfaces to assess molecular complementarity between two cocrystal components. The screening tool was applied to two 
low solubility drugs, namely griseofulvin and spironolactone. Promising coformer candidates were selected from a 
database of 310 pharmaceutically acceptable CCFs, and experimental screening was carried out. Novel solid forms were 
obtained by liquid-assisted grinding and were characterised by XRPD, DSC, TGA and IR. One new cocrystal of griseofulvin 
and two new cocrystals of spironolactone were identified, and the crystal structures were determined from the XRPD 
patterns. For these systems, phenols tend to act as successful H-bond donors in forming cocrystals, while carboxylic acids 
only give rise to physical mixtures of the two components. 
Introduction 
The exploration of active pharmaceutical ingredient (API) solid 
state chemistry is an integral part of drug discovery and 
pharmaceutical development.1 Solubility properties and the 
dissolution rate of a solid drug are key parameters in dictating 
oral bioavailability.2 With the use of high-throughput screening 
methodology and combinatorial chemistry, the number of 
poorly soluble APIs has risen dramatically.3 Drugs exhibiting 
poor bioavailability are categorised as Biopharmaceutical 
Classification System (BCS) class II and class IV, based on their 
low solubility properties.4 Several approaches in drug 
formulation have been designed to improve drug solubilisation 
in the gastrointestinal tract. Non-covalent approaches include 
the use of cyclodextrin inclusion compounds,5 solid 
dispersions,6 amorphous forms7 as well as salt8 and cocrystal 
formation.9 
Pharmaceutical cocrystals are molecular adducts of definite 
stoichiometry where one component is a neutral API and the 
other is a neutral pharmaceutically acceptable crystal 
coformer (CCF) and both components are solids at room 
temperature.10 The CCFs are usually selected from the GRAS 
(Generally Regarded as Safe)11 and EAFUS (Everything Added 
to Food in the United States)12 lists if the resulting cocrystals 
are to be considered suitable for drug development. The 
benefit of cocrystallisation is that non-ionisable API molecules 
can also be targeted, so the list of potential CCFs is more 
comprehensive than for salt formation. In recent years, the 
exploration of pharmaceutical cocrystals has led to the 
successful enhancement of physicochemical properties of APIs, 
such as thermal, humidity and thermodynamic stability.13 
Other important pharmaceutical properties that have been 
improved through cocrystal formation are clinical performance 
and manufacturability.14 
In 2013, the FDA considered cocrǇƐƚĂůƐ ĂƐ  ‘W/-ĞǆĐŝƉŝĞŶƚ ?
complexes that were treated as drug product intermediates.15 
The new 2016 FDA draft guidance explains that cocrystals 
should be classified as special cases of solvates, where the 
second component is non-volatile.16 From a regulatory 
perspective, a cocrystal will be treated in the same way as a 
new polymorph of the same API and not as a different 
chemical entity, as is the case for salts. The new classification 
has consequences for the development of cocrystals in the 
pharmaceutical industry due to the simplification of the 
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multicomponent complex regulatory landscape. For example, 
it will be possible to use existing regulatory documents to 
establish potency, purity and stability of a cocrystal API.17 
The process of cocrystal screening can generally be broken 
down into sample preparation, characterisation and 
determination of properties.18 Conventional experimental 
cocrystal screens employed are solution based, such as slow 
evaporation, cooling and vapour diffusion.19 These methods 
are useful as they can yield suitable crystals for structure 
determination by single crystal X-ray diffraction. However, 
single crystal growth is inherently slow and there is a high risk 
of hydrates and solvates being formed.20 Furthermore if the 
solubilities of the API and CCF are very different, precipitation 
of the least soluble component is more likely to take place 
rather than the desired cocrystal.21 Neat grinding (NG) and 
liquid-assisted grinding (LAG) experiments were shown to be 
more efficient at identifying cocrystals as they avoid solvent 
competition that can lead to precipitation of individual 
components.22 Moreover, advances in powder X-ray diffraction 
methods mean that crystal structure solutions can be obtained 
from powder data with good accuracy.23 
In this work, we apply a virtual cocrystal screening method24 to 
two BCS class II APIs, griseofulvin (GSF) and spironolactone 
(SPN).25-27 The in silico screening method has been previously 
validated using experimental cocrystal data reported in the 
literature28 and was successfully applied to obtain seven novel 
cocrystals of nalidixic acid.29 This methodology is not limited to 
cocrystal prediction. It can be applied to formation of ionizable 
multi-component adducts such as salts and propensity to form 
solvates for a specific API. The computational approach uses 
calculated molecular electrostatic potential surfaces (MEPS) to 
identify surface site interaction points (SSIPs).24 The SSIPs can 
be used to assess the molecular recognition properties of the 
entire surface of the molecule,30 and here, they are used to 
calculate the solid state interaction site pairing energy, E, 
defined in Equation 1, which is the sum of all intermolecular 
interactions in a solid. The SSIPs of a molecule are each 
ĚĞƐĐƌŝďĞĚďǇĂŶŝŶƚĞƌĂĐƚŝŽŶƉĂƌĂŵĞƚĞƌ ?ɸi, which is positive for 
a H-bond donor site (or positive region on the MEPS) and 
negative for a H-bond acceptor site (or negative region on the 
MEPS). The energy of interaction between two SSIPs, i and j, is 
ŐŝǀĞŶďǇƚŚĞƉƌŽĚƵĐƚɸiɸj. The stability of a solid is estimated by 
a hierarchical pairing of charge-complementary SSIPs to obtain 
E: the most positive SSIP pairs the most negative SSIP, followed 
by sequential association of the second most positive and 
negative SSIPs until no more pairwise interactions can be 
formed.31 ܧ ൌ σ ߝ௜ߝ௝௜௝   Eq. 1 
The difference in the pairing energy between the pure 
ĐŽŵƉŽŶĞŶƚƐĂŶĚƚŚĞĐŽĐƌǇƐƚĂů  ?ȴE) provides a measure of the 
probability of forming a cocrystal (eq. 2): οܧ ൌ െሺܧ௖௖ െ ܧଵ െ ܧଶሻ  Eq. 2 
where Ecc, E1 and E2 are the interaction site pairing energies of 
the cocrystal and the pure solids, 1 and 2, respectively. 
sĂůŝĚĂƚŝŽŶŽĨƚŚĞȴE parameter was recently provided by a CCF 
exchange experiment using caffeine cocrystals.32 The 
experiment involved grinding multiple CCFs with caffeine and 
using the identities of the cocrystals that formed in the 
mixtures to establish a cocrystal stability ranking. The 
experimental stability ranking for the caffeine cocrystals 
ŵĂƚĐŚĞĚƚŚĞƉƌĞǀŝŽƵƐůǇƉƵďůŝƐŚĞĚƌĂŶŬŝŶŐŽĨȴE values.24 
GSF is an antifungal BCS class II drug that has been reported to 
exhibit antiviral and anticancer effects in mammalian 
systems.33 An enhancement in GSF bioavailability was obtained 
by nanoparticle preparation from water-dilutable 
microemulsions,34 the use of drug-polymer solid solutions35 
and nanocapsules.36 In a cocrystal screen, grinding of GSF with 
40 coformers only yielded a 2:1 GSF-acesulfame cocrystal 
hydrate, where the two cocrystal components interact via the 
water molecule.25 The screen also yielded GSF solvates with 
acetonitrile, nitromethane and nitroethane.37 More recently, a 
drug-polymer cocrystal was reported between GSF and 
polyethylene glycol.38 
SPN has been extensively used as a potassium-sparing diuretic. 
It is a non-ionisable BCS class II drug that acts as a steroidal 
aldosterone antagonist.39 Improvement in SPN biovailability 
was obtained by nanosuspension formulation,40 drug 
micronization and the use of ɴ-cyclodextrins.41 In the 
literature, there are also two studies concerned with the 
cocrystallisation of SPN. A 1:1 SPN-saccharin cocrystal 
hemihydrate has been reported, where crystal packing 
remained largely unchanged after dehydration.26 In a cocktail 
grinding study, several CCFs were ground simultaneously with 
SPN,27 and novel powder patterns were obtained with benzoic, 
salicylic and gentisic acid. 
Here we describe the structures of new cocrystals of both GSF 
and SPN that were obtained after in silico screening of a 
database of 310 pharmaceutically acceptable CCFs. 
Experimental 
Virtual cocrystal screen: Molecular structures of GSF, SPN and 
all 310 CCFs were drawn in an extended conformation using 
the TorchLite software,42 so that the functional groups were 
exposed and available for interaction. The structures were 
energy minimised using the XED3 force field implemented in 
TorchLite, and the MEPS were calculated using DFT (B3LYP 6-
31G*) in Gaussian 09.43 The MEPS were then converted into a 
set of SSIPs using the method described previously.27b The 
increase in stability of the 1:1 cocrystal compared to the two 
pure components was estimated for all CCF-GSF and CCF-SPN 
combinations based on the difference in the interaction site 
ƉĂŝƌŝŶŐĞŶĞƌŐŝĞƐ ?ȴE, calculated using Equations 1 and 2 above. 
Materials: GSF, SPN, all selected CCFs and solvents were 
purchased from Sigma-Aldrich and used as received. 
Grinding: Grinding experiments were performed by mixing 
stoichiometric amounts of GSF and SPN (20 mg) with CCFs in a 
5 mL stainless steel grinding jar containing a grinding ball 7 mm 
in diameter. In LAG experiments, 15 µl of acetonitrile or n-
heptane was also added. Neat grinding was carried out for 
some systems where the coformers were highly soluble or had 
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low melting points: phenol, 4-tert-butylphenol, 2-phenyl 
phenol, indole, skatole and xylenols. The mixtures were 
ground on a Retsch MM 200 mixer mill for 20 to 45 minutes at 
30 Hz. 
X-ray Powder Diffraction (XRPD) Measurements: Powder 
samples were mounted on a silicon wafer mount and analyzed 
on a PANalytical CubiX PRO diffractometer with a copper long-
fine focus tube running at 45 kV and 40 mA (ʄ = 1.5418 Å). 
Samples were measured in reflection geometry in the T ?2T 
configuration over a scan range from 2° to 40° 2T with 1.9 s 
exposure per 0.0025° increment. 
Infrared Spectroscopy (IR): IR spectra were recorded with a 
universal ATR sampling accessory on a Perkin-Elmer Spectrum 
100 Fourier transform spectrophotometer over a range from 
400 to 4000 cm ?1 with a resolution of 1 cm ?1 (eight scans). The 
spectra were processed with the Spectrum v 10.03.07 
software. 
Differential Scanning Calorimetry (DSC): DSC measurements 
were performed using a Discovery DSC calorimeter. About 3 
mg of solid material was weighed into a T0 aluminium pan that 
was sealed hermetically with an aluminium lid. Samples were 
equilibrated at 25°C and then heated to 225°C or 235°C at a 
rate of 10°C min ?1. 
Thermogravimetric analysis (TGA): TGA measurements were 
performed on a TA Q5000 instrument. An open alumina 
crucible was used to heat the sample from 25°C to the 
required temperature at a rate of 10°C/min under a nitrogen 
stream. 
XRPD structure determination: For the GSF-4-tert-butylphenol 
ĐŽĐƌǇƐƚĂů ? Ă WĂŶĂůǇƚŝĐĂů y ?WĞƌƚ WZK DW ŝŶƐƚƌƵŵĞŶƚ ǁŝƚŚ
capillary configuration in transmission geometry, focusing 
elliptic mirror and PIXcel detector working at a maximum 
detector active length of 3.347º 2T, was used. Cu<ɲ radiation (ʄ 
= 1.5418 Å) was selected with focalizing 0.01 and 0.02 radians 
Soller slits. The instrument was operated at 45 kV and 40 mA. 
Samples were placed in Lindemann capillaries of diameter 0.7 
mm and were measured from 2° to 70° 2T, with a step size of 
0.013° and a data collection time of 16 hrs. The powder 
pattern was indexed to a monoclinic cell of approximate 
volume 1302 Å3 by means of Dicvol0444 and the space group 
was determined to be P21 from the systematic absences. 
Based on the calculated density, it was established that there 
was one independent molecule of GSF and one independent 
molecule of 4-tert-butylphenol in the asymmetric unit. The 
crystal structure was determined by direct space 
methodologies starting from a molecular model optimized 
with the commercial software SPARTAN by means of the 
program FOX45 with the parallel tempering algorithm. 
Constraints on molecular geometry were applied, in particular 
considering aromatic rings as rigid groups. Several trials of 20 
million runs were performed. Refinement of the structure was 
performed by the Rietveld method50 using FullProf46 and 
converged ƚŽ ʖ2 = 6.212. Figure S1 of the supplementary 
information depicts the final Rietveld plot. 
For the SPN-phenol and SPN-2,5-xylenol cocrystals, solid 
samples were loaded into a 0.7 mm borosilicate capillary.  X-
ray diffraction data were collected (ʄ = 0.82665 Å) at beamline 
I11 at Diamond Light Source,47 using a wide angle (90°) PSD 
detector comprising multiple Mythen-2 modules. Five pairs of 
five-second scans were conducted at room temperature, 
related by a 0.25° detector offset to account for gaps between 
detector modules, in addition to two pairs of one-second scans 
before and afterwards, to check for beam damage to the 
sample. All resulting patterns were summed to give the final 
pattern for structural analysis. Both powder patterns were 
indexed to a single phase using the TOPAS program.48 The new 
unit cells were then fitted using single-phase Pawley 
refinements.49 SPN-phenol crystallised in an orthorhombic unit 
cell and SPN-2,5-xylenol in a monoclinic unit cell. These were 
compared with existing crystal structures for SPN and the 
corresponding CCF in the CCDC, already established from 
single-crystal X-ray diffraction. No match with any single phase 
or mixture of the two phases was found. The starting model 
used for the Rietveld refinement,50 conducted using TOPAS, 
was rigid-body models (represented as z-matrices) of the two 
cocrystal pure components from the single-crystal structures. 
These rigid bodies were allowed to translate and rotate over 
10000 iterations to find the correct minimum. The model for 
the SPN-phenol cocrystal structure was refined using the 
Rietveld ĂŶĚĐŽŶǀĞƌŐĞĚƚŽʖ2 = 7.210. For the SPN-2,5-xylenol 
cocrystal, the Rietveld refinement converged ʖ2 = 6.115. Figure 
S2 and S3 of the supplementary information depict the final 
Rietveld plots for the SPN-phenol and SPN-2,5-xylenol 
cocrystals respectively. 
Results and Discussion 
A database of 310 CCFs was used to calculate a hierarchical list 
based on the stability of the potential GSF and SPN cocrystals 
compared to the sum of the two pure compoŶĞŶƚƐ  ?ȴE 
expressed in kJ mol-1). For a list of all the 310 CCFs used, please 
see the Supporting Information. Table 1 shows the top 35 CCFs 
that are predicted most likely to yield cocrystals with GSF and 
^WE ĂůŽŶŐ ǁŝƚŚ ƚŚĞŝƌ ĐŽƌƌĞƐƉŽŶĚŝŶŐ ȴE values. Both GSF and 
SPN are predicted to form favourable interactions with good 
H-bond donors such as carboxylic acids and phenols, because 
they have carbonyl groups that can act as H-bond acceptors 
and no H-bond donors. GSF was subjected to experimental 
screening with the CCFs from the left side of Table 1 while SPN 
was tested with the right-hand side CCFs. Just over 10% of the 
& ĚĂƚĂďĂƐĞ ǁŝƚŚ ȴE values greater than 10 kJ mol-1 was 
therefore screened for each API. 
 
Figure 1. Chemical structures of GSF, SPN and the CCFs that formed cocrystals as 
judged by XRPD. 
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Table 1. dŽƉƌĂŶŬĞĚ&ƐďĂƐĞĚŽŶA?E. 
Griseofulvin (GSF)  Spironolactone (SPN)  
CCF ȴȵ / kJ mol-1 CCF ȴȵ / kJ mol-1 
3,4-dihydroxybenzoic acid 28.3 3,4-dihydroxybenzoic acid 26.8 
Etidronic acid 27.2 Resorcinol 25.8 
Resorcinol 26.2 Etidronic acid 24.6 
Citric acid 22.8 Sucralose 22.0 
Tartaric acid 22.5 Tartaric acid 20.1 
Camphoric acid 22.2 Citric acid 19.5 
Malonic acid 21.7 Propyl gallate 18.4 
Propyl gallate 20.6 Tert-butylhydroquinone 17.7 
Sucralose 20.2 Malic acid 17.1 
Malic acid 20.0 Oxalic acid 16.6 
Oxalic acid 19.3 3-hydroxybenzoic acid 16.3 
Tert-butylhydroquinone 18.9 4-hydroxybenzoic acid 16.2 
2,5-dihydroxybenzoic acid 18.4 Fumaric acid 16.1 
3-hydroxybenzoic acid 17.8 2,5-dihydroxybenzoic acid 15.5 
4-hydroxybenzoic acid 17.7 L-rhamnose 15.0 
L-rhamnose 16.7 Sucrose 14.6 
Succinic acid 15.7 Maltose 14.3 
Thiodipropionic acid 15.4 L-tyrosine 13.8 
Ascorbic acid 14.7 Succinic acid 12.8 
L-tyrosine 14.6 Thymol 12.7 
Sucrose 14.5 Thiodipropionic acid 12.6 
Maltose 14.2 2-phenyl phenol 12.5 
L-glutamic acid 14.0 Ascorbic acid 12.5 
Adipic acid 13.5 Urea 12.5 
Folic acid 12.8 2,4-dihydroxybenzoic  acid 12.5 
Taurine 12.2 L-glutamic acid 12.4 
1-hydroxy-2-naphthoic acid 11.8 Butylated hydroxytoluene 11.8 
2,5-xylenol 11.4 1-hydroxy-2-naphthoic acid 11.5 
2-phenyl phenol 11.4 2,5-xylenol 11.4 
4-tert-butylphenol 11.1 Taurine 11.3 
Pyridoxine 11.1 Adipic acid 11.3 
Skatole 10.7 4-tert-butylphenol 11.0 
D-isoascorbic acid 10.6 3,4-xylenol 10.4 
Phenol 10.5 Phenol 10.1 
D-ribose 10.5 Folic acid 9.8 
 
 
Table 2.  Crystallographic data for griseofulvin and spironolactone cocrystals. 
 GSF ʹ 4-tert-butylphenol SPN-phenol  SPN-2,5-xylenol 
Stoichiometry 1:1 1:1 1:1 
crystal system Monoclinic Orthorhombic Monoclinic 
space group P21 P212121 P21 
a (Å) 13.10068 (14) 18.5914(4) 24.7971(6) 
b (Å) 8.65708 (10) 22.6434(5) 10.2080(3) 
c (Å) 11.62420 (15) 6.4703(2) 6.3069(1) 
ɲ (°) 90 90 90 
ɴ (°) 98.9448 (8) 90 112.538(2) 
ɶ (°) 90 90 90 
Z 2  2 2 
V (Å3) 1302.31 2723.8(1) 1474.52(6) 
Indices of fit ʖ2 = 6.212 ʖ2 = 7.210 ʖ2 = 6.115 
CCDC 1517121 1517122 1517123 
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Experimental cocrystal screen 
Liquid-assisted grinding (LAG) was the experimental method of 
choice due to efficiency and speed. The chemical structures of 
the two APIs and the CCFs that led to successful 
cocrystallisation by this method are shown in Figure 1. 
Griseofulvin 
Cocrystal formation was initially studied by LAG of 1:1 
stoichiometric ratios of GSF with the corresponding CCFs using 
n-heptane as a catalytic solvent. This solvent does not readily 
form solvates with small organic molecules and minimises 
sample dissolution due to the low polarity. The LAG mixtures 
were analysed by XRPD to identify the form and crystallinity of 
the samples. A system was defined as a hit if, following 
grinding, it displayed a different powder pattern compared to 
the patterns of the two pure components. Analysis of the 
XRPD patterns revealed that physical mixtures of the 
components or peaks corresponding to pure GSF were 
obtained in most cases (data not shown). The grinding of a 1:1 
GSF and 4-tert-butylphenol mixture for 45 minutes at 30 Hz 
gave a powder pattern different from the pure components 
but the crystallinity of the sample was poor. Acetonitrile was 
tried as an alternative LAG solvent under the same grinding 
conditions and a highly crystalline phase was obtained (Figure 
2a, green trace). 
 
Figure 2. XRPD patterns of (a) griseofulvin (blue), 4-tert butylphenol (red) and a 1:1 
mixture after LAG (green); (b) spironolactone (blue), phenol (red) and a 1:1 mixture 
after LAG (green); (c) spironolactone (blue), 2,5-xylenol (red) and a 1:1 mixture after 
LAG (green). 
Furthermore, the reflections arising from the starting materials 
were absent, suggesting that a new pure phase has been 
obtained. The new XRPD pattern was compared to the 
calculated XRPD pattern of a GSF-acetonitrile solvate that has 
been previously discovered (CCDC refcode PINMOQ) 35. The 
powder pattern obtained from the crystal structure of the GSF-
acetonitrile solvate was completely different from that of the 
one obtained following the LAG mixture of GSF and 4-tert-
butylphenol.  
The thermal stability of this sample was also analysed by DSC 
(Figure 3a). The endothermic peaks that do not correspond to 
the melting points of the pure components suggest a cocrystal. 
The thermogram shows a single sharp endotherm with melting 
onset at 151.5°C and a peak at 153.4°C, which is between the 
melting points of GSF (220.2°C) and 4-tert-butylphenol 
(100.0°C). This observation is consistent with the majority of 
previously reported cocrystals.51 
 
Figure 3. DSC traces of (a) griseofulvin (blue), 4-tert-butylphenol (red) and the 1:1 
griseofulvin-4-tert-butylphenol cocrystal (green); (b) spironolactone (blue), phenol (red) 
and the 1:1 spironolactone-phenol  cocrystal (green); (c) spironolactone (blue), 2,5-
xylenol (red) and the 1:1 spironolactone-2,5-xylenol  cocrystal (green). 
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Figure 4. TGA traces of (a) the 1:1 griseofulvin-4-tert-butylphenol cocrystal; (b) the 1:1 
spironolactone-phenol cocrystal and (c) the 1:1 spironolactone-2,5-xylenol  cocrystal. 
Weight loss from the cocrystal sample on heating was studied 
by TGA (Figure 4a). The observed weight loss of 29.5% 
corresponds to the evaporation or sublimation of 4-tert-
butylphenol from a 1:1 cocrystal (theoretically 29.8% of the 
overall molecular weight). There is a single melting endotherm 
observed during the heating process of the cocrystal at 
approximately 153°C. It is likely that under the sealed-pan 
conditions of the DSC experiment, melting of the cocrystal 
occurs at a lower temperature than the loss of 4-tert-
butylphenol. In the open-pan TGA experiment, the CCF loss 
can occur at a temperature below the melting point of the 
cocrystal.  Although the TGA temperature range is 
considerably lower than the boiling point of 4-tert-butylphenol 
(237°C),52 sublimation at a lower temperature has been 
reported previously for cocrystals.53 
The new phase was analyzed by solid-state infrared 
spectroscopy (IR). Changes in the IR spectrum are consistent 
with different intermolecular interactions in the mixed phase 
compared with the pure components (Figure S4, Appendix). 
For example, the OH stretch at 3224 cm-1 in 4-tert-butylphenol 
is shifted to 3279 cm-1 in the new phase.  
The crystal structure of the cocrystal was determined from the 
XRPD pattern. The GSF:4-tert-butylphenol cocrystal crystallizes 
in the monoclinic system with space group P21 and one 
molecule of each component in the asymmetric unit. 
Molecules of GSF interact through C ?Cl···O halogen bonds 
creating chains parallel to the crystallographic 21 screw axis 
(O3···Cl 3.23 Å, O4···Cl 3.22 Å). The main interaction leading to 
cocrystal formation is a H-bond between the 4-tert-
butylphenol H-bond donor and the cyclohexenone carbonyl 
group (Figure 5a). 
 
Figure 5. Crystal structures of (a) the 1:1 griseofulvin-4-tert-butylphenol cocrystal 
[d(O1-O2) = 2.545 Å, d(O3-Cl) = 3.231 Å), d(O4-Cl) = 3.216 Å)], (b) the 1:1 
spironolactone-phenol cocrystal [d(O1-O2) = 2.767 Å)] and (c) the 1:1 spironolactone-
2,5-xylenol cocrystal [d(O1-O2) = 2.891 Å]. The black dotted lines represent H-bonds. 
Spironolactone 
LAG experiments were initially carried out for 1:1 
stoichiometric ratios of SPN to CCFs in the presence of n-
heptane for 45 minutes at 30 Hz. This led to amorphisation as 
indicated by a reduction in intensity and sharpness of the X-ray 
reflections after grinding. To reduce the energy input, the 
grinding time was reduced to 25 minutes. Novel XRPD patterns 
were obtained on grinding SPN with CCFs 2,5-
dihydroxybenzoic acid, 2,5-xylenol and phenol. The SPN-2,5-
dihydroxybenzoic acid XRPD pattern was already reported in a 
previous study,38 therefore no further work was carried out on 
this system. The SPN-2,5-xylenol and SPN-phenol materials 
obtained were highly crystalline (green traces in Figures 2b and 
2c, respectively) and established as phase pure by Pawley 
fitting of the patterns. 
DSC experiments for both new forms showed a sharp, single 
melting endotherm with a melting point between those of the 
starting materials, further suggesting cocrystal formation. The 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 7  
Please do not adjust margins 
Please do not adjust margins 
SPN-phenol system has a melting onset at 110.0°C (peak at 
112.3°C, Figure 3b green trace), while the SPN-2,5-xylenol 
material has a melting onset at 95.4°C (peak at 96.9°C, Figure 
3c green trace). 
TGA of the SPN-phenol cocrystal showed a steady weight loss 
starting at the beginning of the heating process and still 
occurring at 225°C. The early change in the sample mass could 
be caused by the volatile nature of phenol, while further 
weight loss at high temperatures is most likely due to chemical 
degradation of the compound. In the TGA trace of the SPN-2,5-
xylenol cocrystal, two events were observed: a weight loss of 
15.4% between 83.2°C and 116.4°C, followed by another loss 
of 7.8% between 179.2°C and 205.9°C. The total weight loss of 
23.2% can be assigned to the loss of 1 molecule of 2,5-xylenol. 
There are also obvious differences between the IR spectra of 
the mixtures and those of the pure solids observed for both of 
these systems (Figure S5 and S6, Appendix). 
Crystal structures of the cocrystals were determined from the 
XRPD patterns. The SPN-phenol cocrystal has an orthorhombic 
cell with space group P212121 and one molecule of each 
component in the asymmetric unit. The phenol group forms H-
bonds as a donor with the cyclohexanone carbonyl group 
(Figure 5b). The SPN-2,5-xylenol cocrystal has a monoclinic cell 
with space group P21 and one molecule of each component in 
the asymmetric unit. Molecules of SPN interact with 2,5-
xylenol molecules through H-bonds between the phenol donor 
and the furanone acceptor (Figure 5c). 
 
Conclusions 
Based on a virtual screening method for cocrystal prediction, 
an experimental strategy was designed and applied to discover 
novel cocrystals of two non-ionisable APIs of low aqueous 
solubility, GSF and SPN. The computational tool compares the 
stability of a cocrystal to the two components using SSIPs to 
calculate the difference in the solid state interaction site 
ƉĂŝƌŝŶŐ ĞŶĞƌŐŝĞƐ  ?A?E). A database of 310 potential CCFs was 
screened using this approach, and the 35 CCFs that showed 
ƚŚĞ ŚŝŐŚĞƐƚ ǀĂůƵĞƐ ŽĨ A?E were subjected to experimental 
investigation using liquid-assisted grinding. One GSF cocrystal 
and two SPN cocrystals were identified, and the crystal 
structures of the cocrystals were determined from the X-ray 
powder diffraction patterns. The cocrystals were further 
analysed by DSC, TGA and IR. Although the identification of 
three cocrystals after screening 70 CCFs could be seen as a 
modest success rate, this study demonstrates that 
computational prediction can be successfully applied to APIs 
where cocrystal design is difficult due to limited H-bonding 
potential. 
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